Nivolumab plus 5-ALA light treatment for pleural mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have unresectable malignant pleural mesothelioma (a cancer lining of the lung that surgery can’t remove).
- Your cancer has progressed after 1–2 prior chemotherapy treatments that included platinum and pemetrexed, and you have measurable visible disease.
- Your general health allows activity most of the time (ECOG performance status 0–1).
- Your care team must be able to reach the tumor during a thoracoscopy procedure for pleurodesis (or a catheter/planned palliative pleural procedure).
- You must have confirmed diagnosis from expert pathology review and available tumor tissue (stored or new).
- You can take nivolumab safely: no past anti–PD-1/PD-L1 immunotherapy in the last 5 years, no allergy to nivolumab, and no major heart/lung/kidney/liver or uncontrolled infection problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This study tests proton beam radiation aimed at one side of the chest in people with malignant pleural mesothelioma who are not yet having chemotherapy. The goal is to control the cancer while preserving breathing and quality of life for the right patients.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
Hear when a new Malignant Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.